- Home
- ADI vs PFE Comparison
ADI vs PFE Comparison
Compare ADI & PFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADI
- PFE
- Stock Information
- Founded
- ADI 1965
- PFE 1849
- Country
- ADI United States
- PFE United States
- Employees
- ADI N/A
- PFE N/A
- Industry
- ADI Semiconductors
- PFE Biotechnology: Pharmaceutical Preparations
- Sector
- ADI Technology
- PFE Health Care
- Exchange
- ADI Nasdaq
- PFE Nasdaq
- Market Cap
- ADI 109.5B
- PFE 134.2B
- IPO Year
- ADI 1972
- PFE N/A
- Fundamental
- Price
- ADI $224.12
- PFE $24.60
- Analyst Decision
- ADI Buy
- PFE Hold
- Analyst Count
- ADI 21
- PFE 13
- Target Price
- ADI $255.53
- PFE $29.75
- AVG Volume (30 Days)
- ADI 3.4M
- PFE 46.7M
- Earning Date
- ADI 08-20-2025
- PFE 08-05-2025
- Dividend Yield
- ADI 1.77%
- PFE 7.00%
- EPS Growth
- ADI N/A
- PFE N/A
- EPS
- ADI 3.68
- PFE 1.89
- Revenue
- ADI $9,818,656,000.00
- PFE $63,833,000,000.00
- Revenue This Year
- ADI $14.21
- PFE N/A
- Revenue Next Year
- ADI $11.64
- PFE N/A
- P/E Ratio
- ADI $60.90
- PFE $12.98
- Revenue Growth
- ADI N/A
- PFE 13.53
- 52 Week Low
- ADI $158.65
- PFE $20.92
- 52 Week High
- ADI $247.73
- PFE $30.43
- Technical
- Relative Strength Index (RSI)
- ADI 40.53
- PFE 52.19
- Support Level
- ADI $221.15
- PFE $23.86
- Resistance Level
- ADI $225.64
- PFE $24.89
- Average True Range (ATR)
- ADI 4.48
- PFE 0.47
- MACD
- ADI -0.92
- PFE 0.01
- Stochastic Oscillator
- ADI 40.26
- PFE 61.11
About ADI Analog Devices Inc.
Analog Devices is a leading analog, mixed-signal, and digital-signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers; more than half of its chip sales are to industrial and automotive end markets. ADI's chips are also incorporated into wireless infrastructure equipment.
About PFE Pfizer Inc.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.